News & Events about Ocugen Inc.
Globe Newswire
2 months ago
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. (NASDAQ:OCGN Get Rating) Director Junge Zhang purchased 200,278 shares of the companys stock in a transaction on Wednesday, June 14th. The stock was bought at an average price of $0.50 per share, for a total transaction of $100,139.00. Following the completion of the purchase, the ...
Globe Newswire
4 months ago
Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)Received Orphan Drug Designation (ODD) from the FDA for OCU410ST for the ...
Globe Newswire
5 months ago
MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live ...
Globe Newswire
5 months ago
Favorable safety and tolerability profile related to OCU400 investigational product candidateInitial clinical data from low and medium dose cohorts indicates positive trend in Multi-luminance mobility testing and Best-Corrected Visual Acuity scores for OCU400 treated eyes71.4% (5/7) of OCU400 ...